Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ablynx NV stock logo
ABLYF
Ablynx
$50.63
$50.63
$12.50
$55.04
$3.81B1.995,063 shsN/A
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
$119.99
$119.23
$99.74
$120.05
$4.72B0.47148,695 shs390,921 shs
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$1.74
+1.2%
$2.24
$1.64
$12.51
$574.37M0.859.02 million shs9.30 million shs
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
$0.18
$113.43
$34.53
$114.20
$6.94M2.05891,560 shsN/A
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
$178.75
$176.25
$108.82
$189.99
$10.93B0.13572,759 shsN/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ablynx NV stock logo
ABLYF
Ablynx
0.00%0.00%0.00%0.00%0.00%
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
0.00%0.00%0.00%0.00%0.00%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
+1.78%-7.03%-1.83%-47.08%-78.55%
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
0.00%0.00%0.00%0.00%0.00%
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ablynx NV stock logo
ABLYF
Ablynx
N/AN/AN/AN/AN/AN/AN/AN/A
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
N/AN/AN/AN/AN/AN/AN/AN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
4.7006 of 5 stars
4.31.00.04.21.84.21.3
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
0.689 of 5 stars
0.00.00.04.50.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ablynx NV stock logo
ABLYF
Ablynx
0.00
N/AN/AN/A
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
0.00
N/AN/AN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
2.50
Moderate Buy$12.22602.43% Upside
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
0.00
N/AN/AN/A
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest XLRN, ONCE, CBPO, ABLYF, and IOVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$17.00 ➝ $2.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $8.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $10.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/9/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/9/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Perform
5/9/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $25.00
5/9/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
5/9/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$32.00 ➝ $20.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ablynx NV stock logo
ABLYF
Ablynx
$62.73M60.74N/AN/A$2.71 per share18.68
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
$503.70M9.38$5.01 per share23.93$45.09 per share2.66
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$164.07M3.54N/AN/A$2.33 per share0.75
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
$64.72M0.11N/AN/A$13.15 per share0.01
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
$92.52M118.15N/AN/A$11.74 per share15.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ablynx NV stock logo
ABLYF
Ablynx
-$122.67MN/A0.00N/AN/AN/AN/AN/A
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
$138.81M$4.2833.5227.90N/A27.43%8.32%7.64%N/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$372.18M-$1.24N/AN/AN/A-176.49%-49.71%-39.18%8/6/2025 (Estimated)
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
-$78.82M-$2.11N/AN/AN/A-358.41%-59.10%-33.13%N/A
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
-$166.03M-$4.21N/AN/AN/A-226.01%-32.11%-29.45%N/A

Latest XLRN, ONCE, CBPO, ABLYF, and IOVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$0.25-$0.36-$0.11-$0.36$83.40 million$49.32 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ablynx NV stock logo
ABLYF
Ablynx
N/AN/AN/AN/AN/A
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
N/AN/AN/AN/AN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/AN/AN/AN/AN/A
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
N/AN/AN/AN/AN/A
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ablynx NV stock logo
ABLYF
Ablynx
N/AN/AN/A
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
N/A
12.01
10.13
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/A
4.18
3.64
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
0.35
4.67
4.35
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
N/A
12.14
12.14

Institutional Ownership

CompanyInstitutional Ownership
Ablynx NV stock logo
ABLYF
Ablynx
N/A
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
34.77%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
77.03%
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
88.37%
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
90.35%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ablynx NV stock logo
ABLYF
Ablynx
N/A75.25 millionN/ANot Optionable
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
2,26939.36 millionN/AOptionable
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
500333.93 million299.54 millionOptionable
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
36838.52 millionN/ANo Data
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
31261.16 million60.12 millionOptionable

Recent News About These Companies

Acceleron advances cold fusion technology
Acceleron Banks on Muons for Colder Fusion
Acceleron attracts turbocharged demand for debut Swissie
Merck confirms $11.5bn Acceleron takeover deal
ORBIMED CAPITAL GP II LLC's Net Worth
XLRN Historical Data
MSD eyes March FDA decision on PAH drug sotatercept
Astellas Pharma Inc
HempStreet partners with MGC Pharma launches ArtemiC
Acceleron Corp Becomes a Digital Correspondent Bank
Pharma Contract Sales Market Report 2022-2032

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ablynx stock logo

Ablynx OTCMKTS:ABLYF

$50.63 0.00 (0.00%)
As of 04/30/2019

Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

China Biologic Products stock logo

China Biologic Products NASDAQ:CBPO

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.

Iovance Biotherapeutics stock logo

Iovance Biotherapeutics NASDAQ:IOVA

$1.74 +0.02 (+1.16%)
Closing price 04:00 PM Eastern
Extended Trading
$1.74 0.00 (0.00%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Spark Therapeutics stock logo

Spark Therapeutics NASDAQ:ONCE

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.

Acceleron Pharma stock logo

Acceleron Pharma NASDAQ:XLRN

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.